PROTEOMIC SCREENING IDENTIFIES MEGAKARYOCYTE DERIVED PF4/CXCL4 AS A CRITICAL DRIVER OF MYELOFIBROSIS

EHA Library, Alessandro Malara, 385452

RUXOLITINIB AND MAGROLIMAB INCREASES CALRETICULIN IN MYELOFIBROSIS CD34+ CELLS IN VITRO. PROOF OF CONCEPT FOR COMBINATION THERAPY.

EHA Library, Ciro Rinaldi, 385453

REVUMENIB IN PATIENTS WITH ACUTE LEUKEMIAS: COMPASSIONATE USE PROGRAM EXPERIENCE

EHA Library, C. Michel Zwaan, 386390

CAPILLARY BLOOD SAMPLING ALLOWS FEASIBLE METHOD FOR VENETOCLAX CONCENTRATION MEASUREMENT IN AN ACADEMIC MULTICENTER CLINICAL TRIAL CONTEXT

EHA Library, Sari Kytölä, 386391

NOVEL GENES EXHIBITING FUNCTIONAL RELEVANCE IN KOREAN PATIENTS WITH BLASTIC PLASMACYTOID DENDRITIC CELL NEOPLASM

EHA Library, Jiyeon Kim, 386392

HOMOHARRINGTONINE AND CYTARABINE COMBINED WITH VENETOCLAX (HAV) FOR ADULT PATIENTS WITH DE NOVO AML

EHA Library, Xiao-Hua Luo, 386393

REAL-WORLD DATA AS SUPPLEMENTARY CONTROLS FOR THE PROSPECTIVE RANDOMIZED HOVON-103 TRIAL IN INTENSIVELY TREATED ELDERLY ACUTE MYELOID LEUKEMIA PATIENTS

EHA Library, Sjoerd Hermans, 386394

RESULTS OF NON-CHEMOTERAPEUTIC TREATMENT OF PATIENTS WITH DE NOVO ACUTE PROMYELOCYTIC LEUKEMIA

EHA Library, Vera Troitskaya, 386395

COMPARISON OF VENETOCLAX-BASED INDUCTION THERAPY OR 3+7 FOLLOWED BY ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION FOR NEWLY DIAGNOSED AML PATIENTS

EHA Library, Tran-Der Tan, 386397

ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION IMPROVES OVERALL AND RELAPSE-FREE SURVIVAL IN PREGNANT WOMEN WITH ACUTE MYELOID LEUKEMIA

EHA Library, Vera Troitskaya, 386398

VENETOCLAX PLUS HYPOMETHYLATING AGENTS VERSUS INTENSIVE CHEMOTHERAPY FOR HEMATOLOGICAL RELAPSE OF MYELOID MALIGNANCIES AFTER ALLO-HSCT

EHA Library, Zhangjie Chen, 386399

OUTPATIENT INITIATION OF VENETOCLAX-AZACITIDINE FOR SELECTED ACUTE MYELOID LEUKEMIA PATIENTS IS FEASIBLE AND SAFE: A REAL WORLD SINGLE CENTER ANALYSIS

EHA Library, Roi Gat, 386400

REAL-WORLD MANAGEMENT AND OUTCOMES FOR NEWLY DIAGNOSED AML PATIENTS INITIATING VENETOCLAX AND HYPOMETHYLATING AGENTS IN US COMMUNITY PRACTICE

EHA Library, Yuexi Wang, 386401

NOVEL PROGNOSTIC MODEL FOR RELAPSE IN PATIENTS WITH ACUTE MYELOID LEUKEMIA RECEIVING HAPLOIDENTICAL HEMATOPOIETIC STEM CELL TRANSPLANTATION

EHA Library, Qi Wen, 386402

DIAGNOSIS AND TREATMENT OF T/MYELOID MIXED PHENOTYPE ACUTE LEUKAEMIA (T/M-MPAL)- A UK SINGLE CENTRE EXPERIENCE

EHA Library, Enas Abusalim, 386403

GILTERITINIB MAINTENANCE AFTER ALLOGENEIC STEM CELL TRANSPLANTATION FOR FLT3 MUTATED ACUTE MYELOID LEUKEMIA

EHA Library, Andrius Žučenka, 386404

PREVALENCE AND CLINICAL SIGNIFICANCE OF GERMLINE MUTATIONS IN ACUTE MYELOID LEUKEMIA PATIENTS - A SINGLE-CENTER EXPERIENCE

EHA Library, Chrishthuka Kangatharan, 386405

EFFICACY OF SELINEXOR COMBINED WITH A HYPOMETHYLATING AGENT IN THE TREATMENT OF REFRACTORY/RELAPSED ACUTE MYELOID LEUKEMIA IN PATIENTS EXPOSED TO VENETOCLAX

EHA Library, Jian Zhang, 386406

EFFECTIVENESS OF REINDUCTION CHEMOTHERAPY USING BORTEZOMIB WITH HOMOHARRINGTONINE AND CYTARABINE IN REFRACTORY OR RELAPSED ACUTE MYELOID LEUKEMIA: A PHASE II, MULTICENTER, PROSPECTIVE CLINICAL TRIAL

EHA Library, chengtao zhang, 386407

SAFETY, TOLERABILITY, PHARMACOKINETICS, AND PRELIMINARY ANTITUMOR ACTIVITY OF AZD5991 IN RELAPSED/ REFRACTORY HEMATOLOGIC MALIGNANCIES: A PHASE 1 FIRST-IN-HUMAN STUDY

EHA Library, Pinkal Desai, 386408

CHARACTERISTICS AND OUTCOMES OF PATIENTS WITH WT1 MUTATED MYELOID NEOPLASMS: MAYO CLINIC EXPERIENCE

EHA Library, Rami Basmaci, 386409

A MARKOV DECISION ANALYSIS OF AZACITIDINE AND VENETOCLAX VERSUS INDUCTION CHEMOTHERAPY FOR THE TREATMENT OF MEDICALLY-FIT PATIENTS WITH ACUTE MYELOID LEUKEMIA

EHA Library, Mithunan Ravindran, 386410

AZACITIDINE COMBINED WITH HAG REGIMEN AS INDUCTION THERAPY IN ADULT AML PATIENTS

EHA Library, Hong Pan, 386411

PROGNOSTIC IMPLICATIONS OF WT1 MUTATIONS IN PATIENTS WITH DE NOVO AND RELAPSED ACUTE MYELOID LEUKEMIA IN THE ERA OF NOVEL TARGETED THERAPIES

EHA Library, Himachandana Atluri, 386412

VENETOCLAX PLUS HOMOHARRINGTONINE-BASED CHEMOTHERAPY AS FIRST-LINE TREATMENT FOR ADULTS WITH ACUTE MYELOID LEUKAEMIA: A MULTICENTRE, SINGLE-ARM, PHASE 2 TRIAL

EHA Library, Huafeng Wang, 386413

IMPACT OF MYELOID MUTATION PROFILE ON PCR RESPONSES AND SURVIVAL IN PATIENTS WITH CORE-BINDING FACTOR AML TREATED WITH FLAG BASED REGIMES

EHA Library, Jayastu Senapati, 386414

POTENTIAL DRUG-DRUG INTERACTIONS OF ANTIFUNGAL PROPHYLAXIS AND MIDOSTAURIN IN FLT3-MUTATED ACUTE MYELOID LEUKEMIA – CLINICAL IMPLICATIONS OF THERAPEUTIC DRUG MONITORING

EHA Library, Carolin Joisten, 386415

REAL-WORLD CHARACTERISTICS AND USE OF ANTIEMETIC THERAPIES AMONG PATIENTS WITH ACUTE MYELOID LEUKEMIA TREATED WITH ORAL AZACITIDINE MAINTENANCE THERAPY

EHA Library, Ying Qiu, 386416

A MULTIPARAMETER FLOW CYTOMETRY PANEL FOR SIMPLE AND RAPID DIAGNOSIS OR SCREENING OF MALIGNANT TUMORS AND RELATED DISEASES

EHA Library, Hui Wang, 386417

MODIFICATIONS IN PRIMARY HEMOSTASIS AS ADDITIONAL RISK FACTORS OF BLEEDING IN PATIENTS WITH NEWLY DIAGNOSED ACUTE MYELOID LEUKEMIA (AML): UKRAINIAN PROSPECTIVE STUDY IN A REAL-LIFE COHORT.

EHA Library, Zinaida Stupakova, 386419

EXPRESSION PATTERNS AND CLINICAL RELEVANCE OF IMMUNE CHECKPOINT RECEPTORS AND LIGANDS IN ACUTE MYELOID LEUKEMIA

EHA Library, Milan Jagurinoski, 386420

SINGLE-CELL RNA SEQUENCING REVEALS THE SPATIAL HETEROGENEITY OF EXHAUSTED T CELLS IN BTKI-RESISTANT RICHTER TRANSFORMATION PATIENTS

EHA Library, Yeqin Sha, 386421

T-CELL DYSFUNCTION BY PSEUDOHYPOXIA AND AUTOCRINE PURINERGIC SIGNALING IN CHRONIC LYMPHOCYTIC LEUKEMIA

EHA Library, Eric Eldering, 386422

THE CXCR4-LOW/CD5-HIGH PROLIFERATIVE FRACTION IS ENRICHED IN BTK MUTATIONS AND ANTICIPATES RELAPSE IN IBRUTINIB-TREATED CLL

EHA Library, Federico Pozzo, 386423

DEFECTIVE MITOCHONDRIAL METABOLISM IS AT THE BASIS OF T-CELL DYSFUNCTION IN CHRONIC LYMPHOCYTIC LEUKEMIA PATIENTS

EHA Library, Helga Simon-Molas, 386424

DELETION OF THE SHORT ARM OF CHROMOSOME 8 AND TNFRSF10B LOSS ASSOCIATE TO POOR PROGNOSIS AND DRUG RESISTANCE IN CHRONIC LYMPHOCYTIC LEUKEMIA

EHA Library, Ludovic Jondreville, 386425

XPO1 MUTATIONS IDENTIFY EARLY STAGE CLL CHARACTERIZED BY SHORTER TIME TO FIRST TREATMENT AND ENHANCED BCR SIGNALING

EHA Library, Donatella Talotta, 386426

DISRUPTION IN ONE-CARBON METABOLISM THROUGH MTHFD1 INHIBITION AS NOVEL THERAPEUTIC STRATEGY IN CHRONIC LYMPHOCYTIC LEUKEMIA

EHA Library, Elodie Viry, 386427

ACALABRUTINIB IMPROVES INNATE IMMUNE FUNCTION IN PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA

EHA Library, Rebecca Teglgaard, 386428

DNA METHYLATION ANALYSIS OF B-CELL PROLYMPHOCYTIC LEUKEMIA REVEALS TWO EPIGENETIC SUBTYPES WITH DISTINCT BIOLOGICAL AND CLINICAL FEATURES

EHA Library, Stella Charalampopoulou, 386429

GENETIC DRIVERS IN THE NATURAL HISTORY OF CHRONIC LYMPHOCYTIC LEUKEMIA DEVELOPMENT AS EARLY AS 16 YEARS BEFORE DIAGNOSIS

EHA Library, Pieter Martijn Kolijn, 386430

SINGLE-CELL RNA-SEQUENCING ENABLES TRACKING AND CHARACTERIZATION OF RARE CLL CELLS WITH THE POTENTIAL TO CAUSE REFRACTORINESS.

EHA Library, Terézia Kurucová, 386431

INFECTIONS BEFORE AND DURING IMMUNOGLOBULIN REPLACEMENT THERAPY IN PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA.

EHA Library, Christian Brieghel, 386432

CHRONIC LYMPHOCYTIC LEUKEMIA CELLS ARE SENSITIVE TO THE APOLIPOPROTEIN E-MEDIATED DISRUPTION OF METABOLIC HOMEOSTASIS

EHA Library, Federica Nardi, 386433

IMMUNOGENETICS AND ANTIGEN REACTIVITY PROFILING CONTRIBUTE TO UNRAVELLING THE ONTOGENY OF CLL STEREOTYPED SUBSET #4

EHA Library, Anastasia Iatrou, 386434

MEASUREMENT OF INTRACLONAL DIVERSIFICATION REFINES THE PROGNOSTIC IMPACT OF IGHV MUTATIONS IN CLL

EHA Library, Filippo Vit, 386435

INTEGRATING MULTI-OMICS TO REVEAL THE CLONAL EVOLUTIONARY CHARACTERISTICS IN CLL PATIENTS WITH ZANUBRUTINIB RESISTANCE

EHA Library, Huayuan Zhu, 386436

THE EXPRESSION OF CYTOR LNCRNA HAS POOR PROGNOSTIC VALUE IN CLL PATIENTS AND IS ASSOCIATED WITH MICROENVIRONMENTAL STIMULI.

EHA Library, Lluís Hernández, 386437

EFFECT OF LONG-TERM ZANUBRUTINIB TREATMENT ON T-CELLS IN CHRONIC LYMPHOCYTIC LEUKEMIA PATIENTS: A STUDY CONDUCTED IN PARALLEL WITH THE BGB-3111-304 AND 305 TRIALS.

EHA Library, Maria Andersson, 386438

EXTRACELLULAR VESICLES FROM CHRONIC LYMPHOCYTIC LEUKEMIA CELLS INDUCE THE DIFFERENTIATION OF MONOCYTES INTO NURSE-LIKE CELLS

EHA Library, Nathan DUBOIS, 386439

CD37 AS A MOLECULAR TARGET FOR CAR-T CELLS AGAINST CHRONIC LYMPHOCYTIC LEUKEMIA

EHA Library, Aleksandra Kusowska, 386440

ASSESSMENT OF THE DEVELOPMENT OF B CELL MALIGNANCIES IN A NOVEL MURINE MODEL CARRYING DLEU2 DELETION

EHA Library, Alice Ramassone, 386441

ANALYSIS OF EX-VIVO RESPONSE TO SINGLE DRUGS AND DRUG COMBINATIONS IN CHRONIC LYMPHOCYTIC LEUKEMIA PATIENT SAMPLES

EHA Library, Leonardo Miranda Santana, 386442

NOVEL SPLICE-SITE MUTATION IN PLCG2 ASSOCIATED WITH RESISTANCE TO BTK INHIBITORS

EHA Library, Jialei Qi, 386443

GENE-GENE INTERACTIONS IN PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA WITH VARIOUS CYTOGENETIC PROGNOSTIC FACTORS

EHA Library, Elena Nazarova, 386444

LONG-TERM FOLLOW-UP UPDATE AND MULTIVARIABLE ANALYSES OF FACTORS ASSOCIATED WITH DURATION OF RESPONSE AFTER CD19 CAR T-CELL THERAPY FOR RELAPSED/REFRACTORY CLL

EHA Library, Emily Liang, 386445

TRACKING  DISEASE PARAMETERS BY MRD, CT AND PET IN FIRST LINE CLL PATIENTS TREATED WITH FIXED DURATION IBRUTINIB-VENETOCLAX; INTERIM ANALYSIS OF THE FIRST 30 PATIENTS IN HOVON 158/NEXT STEP TRIAL.

EHA Library, Sabina Kersting, 386448

GENETIC ALTERATIONS AND OUTCOMES WITH FIXED-DURATION IBRUTINIB+VENETOCLAX (IBR+VEN): RESULTS FROM THE PHASE 3 GLOW STUDY IN PATIENTS WITH PREVIOUSLY UNTREATED CLL

EHA Library, Arnon P. Kater, 386449

REAL-WORLD DOSING PATTERNS AND TIME TO NEXT TREATMENT FOR PREVIOUSLY UNTREATED PATIENTS WITH CLL/SLL WITH OR WITHOUT IBRUTINIB DOSE REDUCTION FOLLOWING AN ADVERSE EVENT

EHA Library, Mazyar Shadman, 386450

GENETIC MARKERS AND OUTCOME OF CLL PATIENTS IN COMBINED TIME-LIMITED TREATMENT WITH ANTI-CD20 ANTIBODY + IBRUTINIB, IDELALISIB OR VENETOCLAX IN THE GCLLSG CLL2-BAG, -BCG, -BIG AND -BIO PHASE-II TRIALS

EHA Library, Deyan Yosifov, 386451

MATCHING-ADJUSTED INDIRECT COMPARISON (MAIC) OF PIRTOBRUTINIB VS VENETOCLAX CONTINUOUS MONOTHERAPY IN PATIENTS WITH RELAPSED/REFRACTORY CLL PREVIOUSLY TREATED WITH A COVALENT BTK INHIBITOR

EHA Library, Othman Al-Sawaf, 386452

PHASE 1 STUDY OF JNJ-67856633, A FIRST-IN-HUMAN HIGHLY SELECTIVE MALT1 INHIBITOR, IN RELAPSED/REFRACTORY (R/R) B-CELL NON-HODGKIN LYMPHOMA (B-NHL) AND CHRONIC LYMPHOCYTIC LEUKEMIA (CLL)

EHA Library, Matko Kalac, 386453

A PHASE 1B/2 STUDY OF NAVTEMADLIN COMBINED WITH ACALABRUTINIB IN BTK INHIBITOR NAÏVE PATIENTS WITH RELAPSED/REFRACTORY (R/R) CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) OR SMALL LYMPHOCYTIC LYMPHOMA (SLL)

EHA Library, John C. Byrd, 386454

A PHASE 1 STUDY EVALUATING THE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND PRELIMINARY ANTITUMOR ACTIVITY OF BCL-2 INHIBITOR BGB-11417 IN ADULT PATIENTS WITH MATURE B-CELL MALIGNANCIES

EHA Library, Caixia Li, 386455

LONG-TERM OUTCOMES WITH CONTINUOUS IBRUTINIB IN PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA: ANALYSIS OF TIME TO PROGRESSION

EHA Library, Thomas Kipps, 386456

UPDATED ANALYSIS OF BELLWAVE-001: A PHASE 1/2 OPEN-LABEL DOSE-EXPANSION STUDY OF THE EFFICACY AND SAFETY OF NEMTABRUTINIB FOR THE TREATMENT OF B-CELL MALIGNANCIES

EHA Library, Farrukh Awan, 386457

THE CLL TREATMENT INFECTION MODEL – CLINICAL PROSPECTIVE VALIDATION AS PART OF THE PREVENT-ACALL TRIAL

EHA Library, Carsten Niemann, 386458

SAFETY AND TREATMENT ADHERENCE WITH ACALABRUTINIB IN VERY OLD (≥80Y) AND/OR FRAIL PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) - INTERIM SAFETY ANALYSIS OF THE ONGOING PHASE-II CLL-FRAIL TRIAL

EHA Library, Florian Simon, 386459

CHARACTERIZATION OF ZANUBRUTINIB SAFETY/TOLERABILITY PROFILE AND COMPARISON WITH IBRUTINIB PROFILE IN PATIENTS WITH B-CELL MALIGNANCIES: POST HOC ANALYSIS OF A LARGE CLINICAL TRIAL SAFETY DATABASE

EHA Library, Jennifer R. Brown, 386460

COMPARISON OF TREATMENT-EMERGENT ADVERSE EVENTS OF ACALABRUTINIB AND ZANUBRUTINIB IN CLINICAL TRIALS IN B-CELL MALIGNANCIES: A SYSTEMATIC REVIEW AND META-ANALYSIS

EHA Library, Steven Hwang, 386461

UPDATED SAFETY AND EFFICACY RESULTS OF ZANUBRUTINIB IN PATIENTS WITH B-CELL MALIGNANCIES WHO ARE INTOLERANT OF IBRUTINIB AND/OR ACALABRUTINIB

EHA Library, Mazyar Shadman, 386462

EARLY-STAGE MEASURABLE RESIDUAL DISEASE DYNAMICS AND IGHV REPERTOIRE RECONSTITUTION DURING VENETOCLAX AND OBINUTUZUMAB TREATMENT IN CHRONIC LYMPHOCYTIC LEUKEMIA

EHA Library, Paul Hengeveld, 386463

AN UPDATE OF SAFETY AND EFFICACY RESULTS FROM PHASE 1 STUDY OF LP-108, A NOVEL AND SELECTIVE BCL-2 INHIBITOR, IN PATIENTS WITH RELAPSED OR REFRACTORY B-CELL NON-HODGKIN LYMPHOMAS

EHA Library, Wei Xu, 386464

A FIRST-IN-HUMAN PHASE 1 STUDY OF ORAL LOXO-338, A SELECTIVE BCL2 INHIBITOR, IN PATIENTS WITH ADVANCED HEMATOLOGIC MALIGNANCIES

EHA Library, Michal Kwiatek, 386465

TIME-LIMITED TREATMENT WITH ACALABRUTINIB PLUS OBINUTUZUMAB IN TREATMENT-NAÏVE CHRONIC LYMPHOCYTIC LEUKEMIA PATIENTS: EARLY RESULTS OF AN ONGOING PHASE 2 TRIAL

EHA Library, Jan Burger, 386466

DECISION SUPPORT IN THE CLINICAL ROUTINE FOR RAPID AND RELIABLE DIAGNOSTIC WORKFLOWS WITH THE HEMA.TO PLATFORM

EHA Library, Karsten Miermans, 386467

ZANUBRUTINIB (ZANU) VS BENDAMUSTINE + RITUXIMAB (BR) IN PATIENTS (PTS) WITH TREATMENT-NAÏVE CHRONIC LYMPHOCYTIC LEUKEMIA/SMALL LYMPHOCYTIC LYMPHOMA (CLL/SLL): EXTENDED FOLLOW-UP OF THE SEQUOIA STUDY

EHA Library, Talha Munir, 386468

ZANUBRUTINIB VS IBRUTINIB IN RELAPSED/REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA AND SMALL LYMPHOCYTIC LYMPHOMA (R/R CLL/SLL): IMPACT ON HEALTH-RELATED QUALITY OF LIFE (HRQOL)

EHA Library, Barbara Eichhorst, 386469

REAL-WORLD DURATION OF VENETOCLAX TREATMENT FOR CHRONIC LYMPHOCYTIC LEUKEMIA AND SMALL LYMPHOCYTIC LYMPHOMA

EHA Library, Anna Teschemaker, 386470

A MATCHING-ADJUSTED INDIRECT COMPARISON OF THE EFFICACY AND SAFETY OF ACALABRUTINIB VERSUS ZANUBRUTINIB IN RELAPSED OR REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA

EHA Library, Alan Skarbnik, 386471

CUMULATIVE REVIEW OF HEART FAILURE WITH ACALABRUTINIB IN THE TREATMENT OF CHRONIC LYMPHOCYTIC LEUKEMIA USING DATA FROM CLINICAL TRIALS AND POST-MARKETING EXPERIENCE

EHA Library, Paolo Ghia, 386472

IBRUTINIB FOR TREATMENT OF RELAPSED-REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA: A MATCHING-ADJUSTED INDIRECT COMPARISON OF 3 RANDOMIZED PHASE 3 TRIALS

EHA Library, Paolo Ghia, 386474

VENETOCLAX RETREATMENT AFTER MRD-GUIDED VENETOCLAX +/- IBRUTINIB: THE IMPROVE STUDY COHORT

EHA Library, Lydia Scarfò, 386475

RACIAL DISPARITIES IN REAL-WORLD TREATMENT PATTERNS AND OUTCOMES AMONG PATIENTS WITH CLL

EHA Library, Joanna M. Rhodes, 386476

REAL-WORLD TREATMENT AND OUTCOMES OF PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) RECEIVING FIRST-LINE (1L) THERAPY IN THE NOVEL AGENT ERA: AN INTERNATIONAL STUDY

EHA Library, Frederick Lansigan, 386477

SAFETY AND EFFECTIVENESS IN NAIVE CLL PATIENTS TREATED WITH VEN AND OBI UNDER REAL-WORLD CONDITIONS - COMPARISON OF PATIENTS IN LINE OR OUT OF SCOPE WITH CLL14 TRIAL.

EHA Library, Holger Hebart, 386478

EFFECTIVENESS OF VENETOCLAX ACCORDING TO THE CHARACTERISTICS OF PATIENTS WITH CLL IN MONOTHERAPY AND COMBINATION WITH RITUXIMAB. INTERIM ANALYSIS OF REAL-LIFE DATA FROM VERONE STUDY

EHA Library, Loïc Ysebaert, 386479

REAL-WORLD EFFECTIVENESS OF VENETOCLAX-BASED REGIMENS IN PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA IN ISRAEL: UPDATE FROM THE MULTICENTER PROSPECTIVE REVEAL STUDY

EHA Library, Yair Herishanu, 386480

IMPROVED SURVIVAL OF PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA BETWEEN 1998-2022, INCLUDING THE ERA OF TARGET THERAPIES WITH BCL2 AND BTK INHIBITORS.

EHA Library, Tamar Tadmor, 386481

CML LONG-TERM LEUKEMIC STEM CELL PERSISTENCE IS INFLUENCED BY MYELOFIBROSIS AT DIAGNOSIS

EHA Library, Henrike Jacobi, 386482

ALLELIC POLYMORPHISMS OF KIRS AND HLAS PREDICT FAVORABLE ACHIEVEMENT OF TREATMENT-FREE REMISSION IN CML: RESULTS FROM THE POKSTIC TRIAL, MULTICENTER RETROSPECTIVE OBSERVATIONAL STUDY

EHA Library, Hiroshi Ureshino, 386483

LIMITATIONS OF USING CD26+ LEUKEMIA STEM CELL QUANTITATION IN CML PATIENTS TO ASSESS RESIDUAL LEUKEMIA CLONE

EHA Library, Nikolay Kapranov, 386484

NOVEL THIAZOLIDINEDIONE WITH HDAC INHIBITING PROPERTIES OPTIMIZED FOR CHRONIC MYELOID LEUKEMIA TREATMENT

EHA Library, Anna Rams, 386485

PATHOGENESIS OF TYROSINE KINASE INHIBITOR–ASSOCIATED VASCULAR TOXICITY IN CHRONIC MYELOID LEUKEMIA

EHA Library, Ayala Gover Proaktor, 386486

DEVELOPMENT OF THE HIGHLY ACCURATE AND SENSITIVE METHOD USING THE CHIP-BASED DIGITAL PCR (LOAA) FOR THE DETECTION OF BCR::ABL1 TRANSCRIPTS DURING WHOLE PERIOD OF CHRONIC MYELOID LEUKEMIA TREATMENT

EHA Library, Hyun-Woo Song, 386487

BUPARLISIB A PROMISING THERAPEUTIC APPROACH IN CHRONIC MYELOID LEUKEMIA RESISTANT TO IMATINIB

EHA Library, Ana Bela Sarmento-Ribeiro, 386488

NEXT-GENERATION SEQUENCING (NGS) FOR DETECTING BCR::ABL-INDEPENDENT MUTATIONS IN PATIENTS WITH CHRONIC MYELOID LEUKEMIA WITH RESISTANCE TO TYROSINE KINASE INHIBITOR TREATMENT

EHA Library, Daria Kustova, 386489

CEVIDOPLENIB (SKI-O-703), A NOVEL SYK INHIBITOR, REDUCES ANTIPHOSPHOLIPID ANTIBODY TITERS AND PREVENTS INTRAMYOCARDIAL SMALL ARTERIAL THROMBOSIS IN A MOUSE MODEL OF ANTIPHOSPHOLIPID SYNDROME

EHA Library, Taeyoung Yoon, 388007

RISK FACTORS FOR VENOUS THROMBOEMBOLISM IN ACUTE PROMYELOCYTIC LEUKEMIA

EHA Library, Nikica Sabljić, 388008

SUSTAINED INHIBITION OF PLATELET ACTIVITY AND THROMBOSIS VIA IV AND ORAL ADMINISTRATION OF CS585

EHA Library, Michael Holinstat, 388009